Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

MASLD Pharmacotherapy: Clinical Review

A 2026 review frames MASLD drug choice around fibrosis stage and metabolic phenotype, while trials and US labels keep the approved options distinct.

Why we wrote this. The review's clinical message depends on keeping broad MASLD, the narrower approved MASH population and the separate resmetirom and semaglutide evidence packages distinct.

In this article (6 sections)
  1. MASLD is broader than the treated population
  2. Resmetirom is the liver-directed option
  3. Semaglutide is the metabolic-focused option
  4. The trial percentages are not a drug ranking
  5. Clinical practice still has an eligibility problem
  6. What the review cannot settle yet

A 2026 review of pharmacotherapy for metabolic dysfunction-associated steatotic liver disease, or MASLD, reports no new participant outcomes. Its practical argument is narrower: treatment for the inflammatory form of the disease, called MASH, must be matched to liver fibrosis stage and a person's metabolic profile. The authors identify resmetirom and semaglutide as the two conditionally approved options for patients with stage F2 to F3 fibrosis[1]. Current US labels describe both MASH indications as accelerated approvals, with continued approval dependent on confirmation of clinical benefit[5][6].

That boundary matters because the review discusses a fast-moving treatment field. It does not run a trial, pool effect estimates or compare the two approved medicines head to head. This readout therefore uses the review for its clinical framework, then checks the efficacy claims and US approval language against the primary phase 3 reports and current prescribing information[2].

MASLD is broader than the treated population

MASLD describes steatotic liver disease linked to cardiometabolic risk. MASH is the subset with steatohepatitis, meaning liver-cell injury and inflammation alongside steatosis. Fibrosis stages F2 and F3 indicate moderate to advanced scarring before cirrhosis. The distinction prevents a common overreach: evidence in biopsy-defined, noncirrhotic MASH cannot be applied to everyone with liver fat.

The review says phenotype-based selection should integrate metabolic profile with liver disease stage. It also places non-invasive tests at the center of treatment eligibility and calls for longitudinal monitoring[1]. That is an implementation proposal, not proof that one test or threshold works for every patient. The accessible abstract does not prescribe a universal diagnostic pathway.

This is also why a medicine used for obesity or type 2 diabetes is not automatically a MASH treatment. Disease-specific approval depends on the population and endpoints in the liver trial, followed by the regulator's exact indication. The same molecule can have several indications without making their eligibility rules interchangeable.

Resmetirom is the liver-directed option

Resmetirom is a thyroid hormone receptor beta agonist. In the ongoing MAESTRO-NASH phase 3 trial, 966 adults in the primary analysis had biopsy-confirmed NASH, the former term for MASH, and fibrosis stage F1B, F2 or F3. They were randomized to resmetirom 80 mg, resmetirom 100 mg or placebo. The published efficacy analysis assessed liver histology at week 52[4]. The doses describe the trial and are not instructions.

MASH resolution without worse fibrosis occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared with 9.7% on placebo. Fibrosis improvement by at least one stage without worse disease activity occurred in 24.2%, 25.9% and 14.2%, respectively. Both active groups met both primary histology endpoints versus placebo[4]. Serious adverse-event rates were similar across groups, while diarrhea and nausea were more frequent with resmetirom.

The current US Rezdiffra label covers adults with noncirrhotic MASH and F2 to F3 fibrosis, alongside diet and exercise. The indication uses the accelerated approval pathway based on improvement in MASH and fibrosis[6]. The label also contains monitoring and interaction warnings. Approval is not a claim that histology has already translated into fewer cases of decompensation, liver cancer or death.

Semaglutide is the metabolic-focused option

Semaglutide is a GLP-1 receptor agonist. The ongoing ESSENCE phase 3 trial randomized 1,197 adults with biopsy-defined MASH and F2 to F3 fibrosis in a 2:1 ratio to weekly subcutaneous semaglutide 2.4 mg or placebo for 240 weeks. The published report is a planned week-72 interim analysis of the first 800 participants[3]. Again, this is a trial regimen rather than personal dosing guidance.

MASH resolution without worse fibrosis occurred in 62.9% with semaglutide and 34.3% with placebo. Fibrosis improvement without worse steatohepatitis occurred in 36.8% and 22.4%, respectively. Mean body weight fell by 10.5% with semaglutide and 2.0% with placebo, while gastrointestinal adverse events were more common with semaglutide[3]. Those results came from ESSENCE, not from the new review.

The current US Wegovy injection label includes adults with noncirrhotic MASH and F2 to F3 fibrosis. It states that the accelerated approval rests on improvement in MASH and fibrosis and may depend on a confirmatory trial[5]. Readers can find broader medicine-specific evidence in our semaglutide research overview and label context in the semaglutide regulation section.

The trial percentages are not a drug ranking

The resmetirom and semaglutide percentages should not be placed in one league table. MAESTRO-NASH and ESSENCE used different medicines, trial schedules and analysis times. Their enrolled populations and endpoint definitions also require careful reading. Neither publication randomized people between resmetirom and semaglutide, so the separate placebo comparisons do not establish which medicine works better.

The two strategies are distinct. Resmetirom is liver-directed through thyroid hormone receptor beta. Semaglutide is a metabolic therapy acting at the GLP-1 receptor, and ESSENCE showed substantial weight change. The review's phenotype approach asks clinicians to consider those differences alongside liver stage and comorbid disease. It does not establish a universal sequence, switching rule or combination regimen.

Histology is another boundary. Resolution of steatohepatitis and improvement in fibrosis are clinically meaningful tissue outcomes, but they are surrogate endpoints. The accelerated approvals require later verification of clinical benefit. A better biopsy result cannot yet be presented as direct proof of fewer liver failures or longer survival.

Clinical practice still has an eligibility problem

The review identifies non-invasive assessment as central because repeated biopsy is difficult to use as the routine gateway to treatment. It argues that metabolic risk profiling and follow-up over time will be needed for real-world management[1]. Yet the abstract does not validate one non-invasive test, cutoff or monitoring interval. Those details must come from guidance, labels and clinical judgment rather than being invented from a narrative summary.

Access is only one challenge. Clinicians also have to distinguish broad MASLD from the narrower approved MASH population, identify fibrosis stage and account for other conditions or medicines. Treatment choice may therefore differ between two people who share a liver diagnosis. That is the practical meaning of phenotype-based care, not a claim that a simple algorithm can choose a drug.

What the review cannot settle yet

This review arrives while both phase 3 programs remain ongoing. Mature follow-up is needed to show whether the histology gains persist and lead to fewer clinical liver events. Direct comparative evidence is absent. The best way to identify eligible patients without biopsy, monitor response and decide when a treatment is not helping also remains unsettled.

The useful conclusion is restrained. MASLD pharmacotherapy is no longer a discussion of one undifferentiated fatty-liver population. Current US approvals concern selected adults with noncirrhotic MASH and F2 to F3 fibrosis. Resmetirom and semaglutide reached that point through separate trials with different mechanisms, and their surrogate outcomes still need clinical confirmation.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Was the 2026 MASLD pharmacotherapy review a clinical trial?

No. PubMed classifies it as a review. It enrolled no new participants and reported no original patient outcomes or head-to-head comparison.

Which MASH drugs does the review describe as conditionally approved?

The abstract names resmetirom and semaglutide for patients with F2 to F3 fibrosis. Current US labels describe their MASH indications as accelerated approvals based on improvements in MASH and fibrosis.

Can the resmetirom and semaglutide trial percentages be compared directly?

No. MAESTRO-NASH and ESSENCE were separate placebo-controlled trials with different drugs, schedules and analysis times. They were not a head-to-head comparison.

Do the approvals cover everyone with MASLD?

No. The current US indications concern selected adults with noncirrhotic MASH and moderate to advanced fibrosis consistent with stages F2 to F3, not everyone with liver fat or MASLD.

Sources

  1. [1]Pages et al. (2026): Pharmacotherapy for MASLD, current evidence and challenges in clinical practice (PMID 42918456)Tier 1 · primary↩
  2. [2]NCBI EFetch abstract record for the 2026 MASLD pharmacotherapy review (PMID 42918456)Tier 1 · primary↩
  3. [3]Sanyal et al. (2025): Phase 3 ESSENCE trial of semaglutide in MASH, week-72 interim analysis (PMID 40305708)Tier 1 · primary↩
  4. [4]Harrison et al. (2024): Phase 3 MAESTRO-NASH trial of resmetirom in NASH with liver fibrosis (PMID 38324483)Tier 1 · primary↩
  5. [5]WEGOVY (semaglutide) injection and tablets: current US prescribing information, MASH indication. DailyMed, revised June 2026Tier 1 · primary↩
  6. [6]REZDIFFRA (resmetirom): current US prescribing information, MASH indication. DailyMed, revised July 2026Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars